Camp4 Therapeutics GAAP EPS of -$0.37 (NASDAQ:CAMP)
Camp4 Therapeutics reported a Q3 GAAP EPS of -$0.37, missing estimates by $0.37. The company had $124.5M in cash and equivalents as of September 30, 2026, up from $109.5M at the end of 2025. The earnings report was released on November 6, 2026.
How this was made
The 30-second read
Why it matters
Earnings miss may trigger short‑term sell‑off but cash reserves mitigate immediate liquidity concerns.
Market read
Earnings miss for a small‑cap biotech; relevant for traders with exposure to the sector.
What to watch
Cash balance of $124.5M provides runway; upcoming data releases could offset the miss.
Background
Camp4 Therapeutics is a Nasdaq‑listed biotech focused on oncology therapeutics.
Ticker impact
Camp4 Therapeutics reported Q3 GAAP EPS of -$0.37, a miss versus expectations.
likely pressure as the market prices in the EPS miss
Negative earnings surprise typically triggers sell‑offs in small‑cap biotech stocks.
Market effects
May weigh on other small‑cap biotech peers awaiting earnings.
Limited to U.S. biotech investors.
Low global impact.
Counterpoint
If the miss is already priced in, the stock could rebound on short‑covering.
Key entities
- CompanyCamp4 Therapeutics Corporation
Biotech firm reporting Q3 results.
